• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GNLX

    Genelux Corporation

    Subscribe to $GNLX
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2023

    Exchange: NASDAQ

    Recent Analyst Ratings for Genelux Corporation

    DatePrice TargetRatingAnalyst
    10/29/2024$8.00Buy
    Guggenheim
    8/28/2024$10.00Buy
    ROTH MKM
    11/27/2023$35.00Buy
    H.C. Wainwright
    9/12/2023$40.00Buy
    Maxim Group
    2/15/2023$10.00Speculative Buy
    The Benchmark Company
    See more ratings

    Genelux Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP, Clinical Trial Operations Yu Yong sold $16,291 worth of shares (5,579 units at $2.92), decreasing direct ownership by 10% to 47,640 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:37 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Pharmaceutical Development Cappello Joseph sold $13,832 worth of shares (4,737 units at $2.92), decreasing direct ownership by 8% to 52,266 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:36 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zindrick Thomas sold $31,431 worth of shares (10,764 units at $2.92), decreasing direct ownership by 5% to 191,447 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:39 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Ryder Sean sold $13,067 worth of shares (4,475 units at $2.92), decreasing direct ownership by 9% to 47,621 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:41 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Head of Regulatory Smalling Ralph sold $3,676 worth of shares (1,259 units at $2.92), decreasing direct ownership by 3% to 34,760 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:32 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Head of Regulatory Smalling Ralph was granted 4,172 shares, increasing direct ownership by 13% to 36,019 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:58:47 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Pharmaceutical Development Cappello Joseph was granted 13,350 shares, increasing direct ownership by 31% to 57,003 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:57:32 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Clinical Trial Operations Yu Yong was granted 13,350 shares, increasing direct ownership by 33% to 53,219 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:56:26 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Ryder Sean was granted 10,708 shares, increasing direct ownership by 26% to 52,096 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:55:20 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zindrick Thomas was granted 30,339 shares, increasing direct ownership by 18% to 202,211 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:54:13 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Genelux Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Genelux with a new price target

      Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

      10/29/24 6:26:41 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Genelux with a new price target

      ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

      8/28/24 7:46:18 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Genelux with a new price target

      H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00

      11/27/23 7:16:52 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Genelux with a new price target

      Maxim Group initiated coverage of Genelux with a rating of Buy and set a new price target of $40.00

      9/12/23 9:04:59 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on Genelux with a new price target

      The Benchmark Company initiated coverage of Genelux with a rating of Speculative Buy and set a new price target of $10.00

      2/15/23 9:06:32 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Genelux Corporation SEC Filings

    See more
    • SEC Form 10-Q filed by Genelux Corporation

      10-Q - GENELUX Corp (0001231457) (Filer)

      5/6/25 4:06:34 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Genelux Corporation

      10-K/A - GENELUX Corp (0001231457) (Filer)

      4/29/25 4:05:19 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Genelux Corporation

      S-8 - GENELUX Corp (0001231457) (Filer)

      3/28/25 4:29:17 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Genelux Corporation

      10-K - GENELUX Corp (0001231457) (Filer)

      3/28/25 4:05:54 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Genelux Corporation

      424B5 - GENELUX Corp (0001231457) (Filer)

      3/25/25 5:29:56 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GENELUX Corp (0001231457) (Filer)

      3/25/25 5:27:48 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form FWP filed by Genelux Corporation

      FWP - GENELUX Corp (0001231457) (Subject)

      3/25/25 9:04:44 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - GENELUX Corp (0001231457) (Filer)

      3/25/25 9:03:56 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - GENELUX Corp (0001231457) (Filer)

      2/3/25 6:08:14 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Genelux Corporation

      10-Q - GENELUX Corp (0001231457) (Filer)

      11/14/24 4:01:51 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care